Volume 30, Number 1—January 2024
Research
Molecular Evolution and Increasing Macrolide Resistance of Bordetella pertussis, Shanghai, China, 2016–2022
Table
Antimicrobial-resistance profiles and virulence genotypes of 283 Bordetella pertussis isolates, Shanghai, China, 2016–2022*
Antibiotic | MIC, μg/mL | Total, no (%) | Frequency of genotype profiles, no (%) |
||
---|---|---|---|---|---|
ptxP1/prn1/fhaB3 non-MT28, n = 141 | ptxP3/prn2/fhaB1 non-MT28,† n = 68 | ptxP3/prn2/fhaB1 MT28,‡ n = 74 | |||
Erythromycin | Resistant, >256 | 205 (72.4) | 137 (97.2) | 0 | 68 (91.9) |
Sensitive, <0.064 |
78 (27.6) |
4 (2.8) |
68 (100) |
6 (8.1) |
|
Azithromycin | Resistant, 128 to >256 | 205 (72.4) | 137 (97.2) | 0 | 68 (91.9) |
Sensitive, <0.064 |
78 (27.6) |
4 (2.8) |
68 (100) |
6 (8.1) |
|
Clarithromycin | Resistant, 128 to >256 | 205 (72.4) | 137 (97.2) | 0 | 68 (91.9) |
Sensitive, <0.064 |
78 (27.6) |
4 (2.8) |
68 (100) |
6 (8.1) |
|
Sulfamethoxazole/ trimethoprim | Resistant, >32 | 0 | 0 | 0 | 0 |
Sensitive, 0.064 to <0.008 | 283 (100) | 141 (100) | 68 (100) | 74 (100) |
*MT, multilocus variable-number tandem-repeat analysis type. †Includes 1 MT27-ptxP3/prn3/ptxC2 strain. ‡Includes 1 MT28-ptxP3/prn9/fhaB1 strain.
1These first authors contributed equally to this article.
Page created: November 19, 2023
Page updated: December 20, 2023
Page reviewed: December 20, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.